Meeting
2020 ASCO Virtual Scientific Program
Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor in non-small cell lung cancer.
Authors
Sehhoon Park
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Sehhoon Park , Chan-Young Ock , Minje Jang , Jiwon Shin , Sarah Lee , Kyunghyun Paeng , Jonghanne Park , Young Kwang Chae , Yoon La Choi , Tony S. K. Mok , Se-Hoon Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3120)
DOI
10.1200/JCO.2020.38.15_suppl.3120
Abstract #
3120
Poster Bd #
184
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Biagio Ricciuti
Poster
2022 ASCO Annual Meeting
The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types.
First Author: Jeanne Shen
Poster
2021 ASCO Annual Meeting
Changes in PD-L1 tumor proportion score are associated with CD274 gene (encoding PD-L1) copy number variation in non-small cell lung cancer.
First Author: Stephanie Leigh Alden
Poster
2021 ASCO Annual Meeting
Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).
First Author: Hyojin Kim